Published in Oncogene on December 23, 2013
Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A (2015) 0.84
E2F activators signal and maintain centrosome amplification in breast cancer cells. Mol Cell Biol (2014) 0.83
Increased metastasis with loss of E2F2 in Myc-driven tumors. Oncotarget (2015) 0.82
Targeting the RB-E2F pathway in breast cancer. Oncogene (2016) 0.81
Downregulated miR-31 level associates with poor prognosis of gastric cancer and its restoration suppresses tumor cell malignant phenotypes by inhibiting E2F2. Oncotarget (2016) 0.79
Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures. Nucleic Acids Res (2015) 0.78
Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis. Oncotarget (2015) 0.76
The Quest for Targets Executing MYC-Dependent Cell Transformation. Front Oncol (2016) 0.76
HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound. Oncotarget (2014) 0.76
Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol (2016) 0.75
HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res (2016) 0.75
Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer. Medicine (Baltimore) (2015) 0.75
Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer. J Mammary Gland Biol Neoplasia (2017) 0.75
Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients. Oncoscience (2015) 0.75
Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures. Nat Commun (2017) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
An extended transcriptional network for pluripotency of embryonic stem cells. Cell (2008) 14.64
Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A (2001) 13.30
The regulation of E2F by pRB-family proteins. Genes Dev (1998) 12.77
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A (1992) 8.59
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell (1988) 7.50
Specific protection against breast cancers by cyclin D1 ablation. Nature (2001) 6.94
E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell (1996) 5.26
The Rb/E2F pathway and cancer. Hum Mol Genet (2001) 4.98
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol (1994) 4.49
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr Mol Med (2006) 3.86
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
E2f3 is critical for normal cellular proliferation. Genes Dev (2000) 3.26
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol (2000) 2.47
Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell (2001) 2.29
Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity (2001) 2.09
E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites. Genome Res (2008) 2.07
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci U S A (2006) 1.66
Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol (1997) 1.66
Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res (2011) 1.54
Mouse development with a single E2F activator. Nature (2008) 1.51
E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Mol Cell Biol (2003) 1.50
The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas. Cancer Res (2007) 1.48
ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J Biol Chem (2002) 1.39
The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia (2001) 1.38
Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res (2009) 1.32
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26
Patterns of cell signaling pathway activation that characterize mammary development. Development (2008) 1.02
Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors. Cancer Res (2011) 0.95
The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene (2016) 0.76
Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. Oncogene (2017) 0.75